Anticoagulants can be dangerous drugs. Developed to save lives by preventing and treating thrombosis, these widely used medications are linked to unacceptable levels of morbidity and mortality. According to a study by the Institute for Safe Medication Practices, 8.2% of hospitalized patients on warfarin and 13.6% exposed to heparin experience an adverse drug event. To prevent these events from occurring, clinicians monitor anticoagulation therapy closely. But there are still questions. What is the risk of stroke in a patient who has specified CHADS2 risk factors? What is the recommended perioperative treatment? Find life-saving solutions quickly to these challenges and more with Anticoagulation Therapy: A Point-of-Care Guide, edited by William Dager, Michael Gulseth, and Edith Nutescu. This concise reference is designed with the busy clinician and resident in mind. It provides a quick way to access necessary clinical and therapeutic information that has the potential to improve the lives when many risk factors are at play and time is of the essence. Inside you’ll find: Quick reference elements such as tables figures to easily access key information Clinical pearls and bullets to highlight real life application Selected guideline statements from leading organizations 19 chapters covering a broad range of topics The second book in the Point-of-Care series, Anticoagulation Therapy is led by a team of editors with more than 77 combined years of clinical experience, including insight from 19 contributors. The book is divided into three sections, including: Anticoagulation Medication Management, Conditions Requiring Anticoagulation Therapy, and Practical Monitoring and Coagulation Laboratory Insights.

This book presents the latest evidence and guidelines supporting the use of anticoagulant therapy for various clinical scenarios. The field of anticoagulation therapy is evolving rapidly, particularly since the arrival and widespread adoption of direct oral anticoagulants. Organized in two parts, this book reviews the pharmacologic properties of various anticoagulants and details the clinical applications of anticoagulant therapy. Drugs such as warfarin and unfractionated heparin, as well as parenteral and direct oral anticoagulants are discussed in terms of their pharmacokinetics, drug-disease interactions, dosing strategies, and risk considerations. Clinical applications of anticoagulant therapy in disorders such as acute coronary syndromes, atrial fibrillation, and thrombophilia and in special populations such as pregnant women, the elderly, and in the patient with cancer are highlighted. Clinical vignettes, algorithms, clinical pearls, and self-assessment questions are integrated throughout the book. Featuring contributions from authorities in the field, Anticoagulation Therapy is an essential resource for cardiologists, vascular medicine specialists, hematologists, internists, and all other healthcare professionals who prescribe anticoagulants.

The available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase III trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists.

Given the amount and complexity of information surrounding the the target specific oral anticoagulants a lengthy didactic educational format has the potential to be overwhelming to the reader and difficult to translate and apply to direct patient care. The proposed book will educate clinicians utilizing a series of clinical cases to simultaneously develop the readers’ knowledge base, problem-solving skills, and practically apply their new knowledge to a variety of clinical situations. These will be short focused case presentations that provide critical information and pose questions to the reader at key points in the decision making process. The cases will be relevant to what clinicians will encounter not only on a daily basis, but also reflective of scenarios that clinicians will not encounter regularly, but that they will have to act upon (e.g. a bleeding patient, patient scheduled for elective or emergent procedure, patient with changing renal function, patient on drugs that have a plausible yet unstudied drug interaction with a target specific oral anticoagulant etc). Included in the case studies will be evidence-based discussions (with appropriate references) that provide immediate feedback on the different treatment alternatives that were offered. The case studies will be designed to instruct the reader how to select and effectively utilize the most appropriate agent for a given clinical scenario. They will focus on key features of the target specific oral anticoagulants, what they have in common, how they are unique from each other, as well as illustrating the clinical decision process one should take when selecting an agent or managing a patient already receiving one of the target specific oral agents. ​

This title will be presented as highly practical information pn pharmaceutical antiplatelet and anticoagulation therapy, written in a quick-access, no-nonsense format. The emphasis will be on a just-the-facts clinical approach, heavy on tabular material, light on dense prose. The involvement of the ISCP will ensure that the best quality contributors will be involved and establish a consistent approach to each topic in the series. Each volume is designed to be between 120 and 250 pages containing practical illustrations and designed to improve understand and practical usage of cardiovascular drugs in specific clinical areas.

In this issue of Interventional Cardiology Clinics, guest editor Dr. Luis Ortega Paz brings his considerable expertise to the topic of Antiplatelet and Anticoagulation Therapy in Cardiovascular and Pulmonary Embolism Transcatheter Interventions. Top experts in the field discuss regulation of platelet activation and coagulation; genetic determinants of P2Y12 inhibitors and clinical implications; switching P2Y12 receptor inhibiting therapies; high bleeding risk in patients undergoing coronary and structural heart interventions; and much more. - Contains 13 relevant, practice-oriented topics including antithrombotic therapy in atrial fibrillation patients undergoing coronary stenting; antithrombotic therapy in patients undergoing transcatheter aortic valve replacement; antithrombotic therapy in patients undergoing peripheral artery interventions; antiplatelet therapy in women; and more. - Provides in-depth clinical reviews on antiplatelet and anticoagulation therapy in cardiovascular and pulmonary embolism transcatheter interventions, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet agents; optimal duration of antiplatelet therapy after PCI; Cangrelor and its role in percutaneous coronary intervention; Ticagrelor and its effects beyond the P2Y12 receptor; dyspnea and Reversibly-binding P2Y12 antagonists; PAR receptor inhibition post-PCI; switching P2Y12 receptor inhibiting therapies; antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting; antithrombotic therapy to reduce ischemic events in ACS patients undergoing PCI; and the current role of platelet function testing in PCI and CABG, among other topics.

The first guide to providing systematic anticoagulation care in inpatient settings, this new resource will be welcomed by all pharmacists who practice in or are developing, implementing and maintaining an inpatient anticoagulation service; a review of anticoagulant medications and case examples of issues commonly encountered. Each chapter contains tools, references, policies, competency exams, etc that are included on a companion CD-ROM.

This new edition of an acclaimed text reviews the evidence for best practice in Maternal-Fetal Medicine, to present the reader with the right information, with appropriate use of proven interventions and avoidance of ineffectual or harmful ones. The information is presented in the right format by summarizing evidence succinctly and clearly in tables and algorithms. The aim is to inform the clinician, to reduce errors and "to make it easy to do it right." The volume can be purchased separately or together with the companion volume on Obstetric Evidence Based Guidelines (set ISBN 9780367567033). The Series in Maternal-Fetal Medicine is published in conjunction with the Journal of Maternal-Fetal and Neonatal Medicine. From reviews of previous editions: "An excellent resource with quick and easy protocols... this book has a permanent spot on my shelf." — Doody’s Review Service

In addition to acting as a training guide for pharmacists, pharmacy residents and pharmacy students who seek to practice in areas associated with patients on anticoagulant therapy, the information presented within highlights the growing role of the pharmacist in these contexts. Readers will find useful information on anticoagulant management across all pharmacy practice areas, including the inpatient, ambulatory, emergency services and transitions of care settings. Particular attention is given to summarizing best practices and providing ‘real world’ examples of ways in which pharmacists can be involved in anticoagulation management and the impact of such involvement. In the first major section of the book, each chapter focuses on the role of the pharmacist in the management of medication with a specific type of anticoagulants (e.g. warfarin, heparin and target-specific oral agents) in various healthcare settings. A broader overview of the clinical management of anticoagulation therapy is provided in the second major section, including descriptions of the role of pharmacists in assessing venous thromboembolism risk, ensuring patients receive appropriate prophylactic therapy, and monitoring outcomes.